Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes

[1]  G. Antoni,et al.  Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates , 2019, Scientific Reports.

[2]  A. Evers,et al.  First-in-class positron emission tomography tracer for the glucagon receptor , 2019, EJNMMI Research.

[3]  Y. Hijazi,et al.  A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials , 2018, Diabetes, obesity & metabolism.

[4]  A. Evers,et al.  Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. , 2018, Endocrinology.

[5]  A. Evers,et al.  Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non‐human primates , 2018, Diabetes, obesity & metabolism.

[6]  L. Jermutus,et al.  MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH , 2018, Diabetes.

[7]  P. Hockings,et al.  MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus , 2018, Diabetes.

[8]  R. Scharfmann,et al.  Mitochondrial Protein UCP2 Controls Pancreas Development , 2017, Diabetes.

[9]  M. Tschöp,et al.  GLP-1/glucagon receptor co-agonism for treatment of obesity , 2017, Diabetologia.

[10]  A. Evers,et al.  Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. , 2017, Journal of medicinal chemistry.

[11]  M. Bednarek,et al.  A novel glucagon‐like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice , 2017, Hepatology.

[12]  O. Eriksson,et al.  Fully automated GMP production of [Ga-68]Ga-DO3A-VS-Cys(40)-Exendin-4 for clinical use , 2017 .

[13]  O. Eriksson,et al.  Fully automated GMP production of [ 68 Ga ] GaDO 3 AVS-Cys 40-Exendin-4 for clinical use , 2017 .

[14]  M. Lubberink,et al.  Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  O. Korsgren,et al.  In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4 , 2013, The Journal of Nuclear Medicine.

[16]  Gerard B. Fox,et al.  PET imaging for receptor occupancy: meditations on calculation and simplification , 2012, Journal of biomedical research.

[17]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[18]  Michael E. Lassman,et al.  Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.